mipenem is a new type of β-lactam antibiotic with strong broad-spectrum antibacterial activity and β-lactamase inhibitory effect. It has the powerful anti-gram-positive bacteria characteristics of the first-generation cephalosporins, and the high stability of the third-generation cephalosporins against the broad-spectrum β-lactamase produced by negative bacilli. Negative bacilli have strong antibacterial activity, and Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus faecalis, Bacteroides fragilis, etc., which are easily resistant to β-lactam antibiotics, are also highly sensitive to this product. The antibacterial spectrum of this product includes almost all clinically meaningful pathogenic bacteria, some methicillin-resistant Staphylococcus aureus, and group D Streptococcus is sensitive to imipenem. Cilastatin has no antibacterial effect, but can inhibit dehydropeptidase secreted by renal cells in vivo, so that imipenem is protected from hydrolysis damage. For infections caused by various sensitive bacteria. It is suitable for mixed infections caused by multiple pathogens and aerobic/anaerobic bacteria, and early treatment before pathogens are not identified. For the following infections caused by sensitive bacteria: Intra-abdominal infection ,Lower respiratory infection,Gynecological infection, Septicemia, Urinary tract infection , Bone and joint infection , Skin and soft tissue infection ,Severe endocarditis.
Reyoung pharmaceutical CO.,LTD was established in 1966, is a modern comprehensive pharmaceutical company in China. Reyoung is given the title of National Trustworthy Company for Contract and Credit, Grade AAA Credit Company and Credit Company of Shandong Medical Industry. In the past 50 years, Reyoung inherits the mission Reyoung Pharma, Benefit the public, never stop exploration and innovation, forging ahead with determination and realizing the sustainable healthy development.
Now Reyoung consists of 3 factory sites, covering an area of 1 million square meter, possessing more than 30 workshops(9 categories, and 400 strengths) , focusing on developing , manufacturing and selling Powder for injection(Lyophilized powder for injection is included), Small volume injection, Traditional Chinese Medicine, Tablets, Capsules, Granules, Suppository, Mixtures and APIs.
All the workshops have been passed the Chinese GMP. Reyoung also passed the foreign audit including PIC/S GMP, Ethiopia, Uganda, Kenya, TFDA, NAFDAC, Ghana, Cote d'loire, Pakistan ect. Reyoung focus on the domestic and foreign market. Reyoung processes professional marketing teams, more than 160 representative offices spreading all over China. We commenced international business from 1997, and Reyoung products sell to more than 70 countries and NGOs all over the world.
Audited Supplier 
){kind=link}